155 related articles for article (PubMed ID: 31486880)
1. Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghaffari SH
Ann Hematol; 2019 Dec; 98(12):2719-2727. PubMed ID: 31486880
[TBL] [Abstract][Full Text] [Related]
2. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
3. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
6. The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer.
Xue WJ; Feng Y; Wang F; Li P; Liu YF; Guo YB; Wang ZW; Mao QS
Tumour Biol; 2016 Aug; 37(8):11249-57. PubMed ID: 26945573
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma.
Tian F; Yip SP; Kwong DL; Lin Z; Yang Z; Wu VW
Cancer Epidemiol; 2013 Oct; 37(5):708-13. PubMed ID: 23790641
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
[TBL] [Abstract][Full Text] [Related]
9. Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.
Dong T; Zhang M; Dong Y; Herman JG; van Engeland M; Zhong G; Guo M
Discov Med; 2015 Nov; 20(111):261-71. PubMed ID: 26645898
[TBL] [Abstract][Full Text] [Related]
10. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of the serum
Hu Y; Ma P; Feng Y; Li P; Wang H; Guo Y; Mao Q; Xue W
J Int Med Res; 2019 Jul; 47(7):2890-2900. PubMed ID: 31119967
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas.
Siu LL; Chan JK; Wong KF; Choy C; Kwong YL
Br J Haematol; 2003 Jul; 122(1):70-7. PubMed ID: 12823347
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
15. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
[TBL] [Abstract][Full Text] [Related]
17. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
18. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
19. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
20. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
